Third Rock Ventures is launching a new cancer diagnostics company called Thrive Sciences, according to a new corporation registration filed in Massachusetts last month.
The documents are vague about the new company’s specific targets. But the long list of directors listed on the form — many of whom have substantial expertise in liquid biopsy work — send a strong signal that Thrive will be working around that technology.
Liquid biopsy companies typically work on ways to screen blood for signs of a disease like cancer. Often, the technique is touted as a potential way to catch cancer earlier and improve a person’s chances of survival.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect